Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhefeng Liu

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Pathology Oncology Research : POR|June 30, 2022
Characterizing HDAC Pathway Copy Number Variation in Pan-CancerShuming Yang, Shengzhi Xie, Xinying Shi, et al.
Postgraduate Medical Journal|April 19, 2025
Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective studyZhijuan Du, Xiangwei Ge, Yao Li, et al.
Cancer Pathogenesis and Therapy|December 15, 2025
Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib studyHaitao Tao, Yining Liu, Lijie Wang, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 7, 2025
A Real-Time Solar UVA Dose Monitor Based on Recyclable Azobenzene-Containing Elastomer FabricsTianhao Chen, Zhefeng Liu, Sha Sha, et al.
Translational Lung Cancer Research|March 21, 2025
Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trialsZhefeng Liu, Zhikuan Wang, Jun Zhu, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 11, 2012
Meta-analysis of ALDH2 variants and esophageal cancer in AsiansPing Fang, Shunchang Jiao, Xin Zhang, et al.
Anti-Cancer Drugs|December 8, 2017
Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational studyYong Zhang, Miaomiao Gou, Chun Han, et al.
Medical Oncology (Northwood, London, England)|July 15, 2015
A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancerZhefeng Liu, Zhimin Wei, Yi Hu, et al.
International Immunopharmacology|June 8, 2024
Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institutionYuhui Qin, Teng Zhang, Zhijuan Du, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 25, 2024
Clinical characteristics and survival outcomes in patients with pulmonary sarcomatoid carcinoma: a multicenter retrospective studyZhijuan Du, Yuhui Qin, Yahui Lv, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Pathology Oncology Research : POR|June 30, 2022
Characterizing HDAC Pathway Copy Number Variation in Pan-CancerShuming Yang, Shengzhi Xie, Xinying Shi, et al.
Postgraduate Medical Journal|April 19, 2025
Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective studyZhijuan Du, Xiangwei Ge, Yao Li, et al.
Cancer Pathogenesis and Therapy|December 15, 2025
Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib studyHaitao Tao, Yining Liu, Lijie Wang, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 7, 2025
A Real-Time Solar UVA Dose Monitor Based on Recyclable Azobenzene-Containing Elastomer FabricsTianhao Chen, Zhefeng Liu, Sha Sha, et al.
Translational Lung Cancer Research|March 21, 2025
Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trialsZhefeng Liu, Zhikuan Wang, Jun Zhu, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 11, 2012
Meta-analysis of ALDH2 variants and esophageal cancer in AsiansPing Fang, Shunchang Jiao, Xin Zhang, et al.
Anti-Cancer Drugs|December 8, 2017
Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational studyYong Zhang, Miaomiao Gou, Chun Han, et al.
Medical Oncology (Northwood, London, England)|July 15, 2015
A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancerZhefeng Liu, Zhimin Wei, Yi Hu, et al.
International Immunopharmacology|June 8, 2024
Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institutionYuhui Qin, Teng Zhang, Zhijuan Du, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 25, 2024
Clinical characteristics and survival outcomes in patients with pulmonary sarcomatoid carcinoma: a multicenter retrospective studyZhijuan Du, Yuhui Qin, Yahui Lv, et al.
Pageof 6